Welcome to our dedicated page for American Vanguard SEC filings (Ticker: AVD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The American Vanguard Corporation (NYSE: AVD) SEC filings page on Stock Titan provides structured access to the company’s regulatory disclosures, alongside AI-powered tools that help interpret complex documents. As a diversified specialty and agriculture products company, American Vanguard files periodic and current reports that describe its financial condition, operations, and material events.
Investors can review Form 10-K annual reports and Form 10-Q quarterly reports to see detailed discussions of net sales by U.S. crop, U.S. non-crop, and international categories, cost of sales, gross profit, operating expenses, research and product development spending, and transformation-related items. These filings also present information on debt levels, inventory, net working capital, and other balance sheet metrics that management frequently references in earnings releases.
The company’s Form 8-K current reports highlight specific events, such as the announcement of quarterly results, the extension and amendment of its Third Amended and Restated Loan and Security Agreement, and the reporting of preliminary full-year Adjusted EBITDA. One 8-K explains how American Vanguard defines EBITDA and Adjusted EBITDA, and why management uses these non-GAAP measures in assessing operating performance and in connection with its credit facility.
On this page, AI-generated summaries help explain the key points of lengthy filings, including how new loan amendments affect borrowing capacity, maturity dates, and financial covenants, or how non-recurring charges and product liability items are treated in reconciliations to Adjusted EBITDA. Users can also track governance-related filings, such as those reporting annual meeting voting results for directors, auditor ratification, and advisory compensation proposals.
By combining real-time EDGAR updates with concise AI explanations, this section allows readers to navigate American Vanguard’s SEC disclosures more efficiently, understand the context behind non-GAAP metrics, and follow the company’s financial and corporate developments as reported to regulators.
American Vanguard Corporation director Steven D. Macicek was awarded 17,621 deferred stock units (DSUs) on 08/07/2025 as part of the companys non-management director compensation program tied to the 2025 annual stockholders meeting. Each DSU represents the right to receive one share of common stock upon settlement.
The DSUs were granted at $0, are nontransferable during the recipients service, and carry no voting or dividend rights until settlement. Following the award the reporting persons beneficial ownership is reported as 48,839 shares.
American Vanguard Corporation (AVD) reported that director Scott Baskin was awarded 8,810 shares of common stock on 08/07/2025 as part of the company’s non-management director compensation program. The shares were granted at a price of $0, reflecting an award rather than an open-market purchase.
Following the grant, Mr. Baskin’s reported beneficial ownership increased to 41,997 shares. The filing identifies Mr. Baskin as a director and notes the award was connected to the 2025 annual stockholders' meeting. This is a routine equity award disclosed on Form 4 and does not include additional transactions or derivative positions.
Patrick E. Gottschalk, a director of American Vanguard Corporation (AVD), was awarded 17,621 deferred stock units (DSUs) on 08/07/2025 as part of the companys non-management director compensation program. Each DSU represents the right to receive one share of common stock upon settlement when the recipients service with the company ends; while outstanding the DSUs are nontransferable and carry neither voting nor dividend rights.
Following the award, Gottschalks reported beneficial ownership of AVD common stock is 79,424 shares (direct). The DSUs were granted at a reported price of $0 and are subject to the companys standard DSU agreement.
American Vanguard (AVD) Q2-25 10-Q highlights:
- Net sales grew 1% YoY to $129.3 m; U.S. crop +1%, U.S. non-crop +3%, International flat.
- Cost-of-sales fell 2%, lifting gross margin to 31% (29% LY). Gross profit +7% to $40.5 m.
- Operating expenses -23% to $36.2 m as transformation spending fell to $1.6 m (vs $7.3 m). Operating income swung to $4.4 m (-$9.2 m).
- After $4.5 m net interest and $0.8 m tax expense, quarterly net loss narrowed sharply to $0.8 m (-$11.7 m); EPS -$0.03.
- 1H-25: revenue -7% to $245.1 m; gross margin 29% (30% LY); operating break-even ($0.1 m); net loss $9.3 m vs -$10.2 m.
- Cash used in operations -$39.8 m (vs -$49.4 m LY) driven by $46.2 m drawdown of customer prepayments and $9.8 m inventory build.
- Debt climbed to $189.5 m (12/24: $147.3 m); average borrowing rate 8.4% Q2.
- May-25 Eleventh Amendment cut revolver to $245 m and suspended leverage & FCCR covenants through 2025, adding minimum liquidity & EBITDA tests. Company had $31.8 m available capacity at 6-30-25.
- No dividends permitted under amended facility.
- Material weaknesses in ICFR (Australia, close process, risk assessment) persist.
- Legal exposure: out-of-spec insecticide lots may create material claims; loss not yet estimable.
Management sees early ag-market recovery, expects lower transformation spend and continues talks to extend credit facility (matures Aug-26).